chartexchange

Nuvectis Pharma Inc (NVCT) (Q3 2026) Earnings Call Highlights: Late-Stage Transformation, $140 ...

GuruFocus | Nov 4, 2026 4:06 PM EST

Nuvectis Pharma Inc (NVCT) outlined a bold late-stage pipeline with ciprocapan and NXP200, a cash runway into 2029, and multiple near-term catalysts despite FDA and competitive uncertainties. Related Stocks: NVCT ,

Read original article